CD53

Across TCGA pan-cancer cohorts, CD53 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of CD53’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where CD53 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CD53 is over-expressed in tumor, although a few such as LSCC show the opposite, repressed pattern.

CCRCC, PDAC, and LSCC are the cancer types where CD53 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CD53 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	II,III,IV	+1.173	<.001	10	view →
PDAC	Female	II,III,IV	+1.353	<.001	6	view →
LSCC	Male	II,III,IV	−0.190	.026	2	view →
COAD	Female	IV	+0.633	.043	1	view →
LUAD	Male	All	+0.160	.022	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

CD53–CCRCC

Open the CCRCC breakdown →